Supriya Lifescience Limited — Updates, 28-10-2024: Press Release

Supriya Lifescience Ltd. reported a strong Q2 FY25, with revenues increasing by 18.6% year-over-year to Rs. 166.1 crore. Gross profit rose 53.1% to Rs. 120.13 crore, while EBITDA surged 103.8% to Rs. 64.72 crore, achieving a 39.0% margin. Profit After Tax (PAT) almost doubled to Rs. 46.15 crore, with a PAT margin of 27.8%. The company continues to expand its global footprint and launched several new projects, driving growth in the anaesthetic and anti-asthmatic segments.